

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

NOVARTIS CORP

2. Address:

701 PENNSYLVANIA AVE NW #725, WASHINGTON, DC 20004

3. Principal place of business (if different from line 2):

4. Contact Name: ANDREA MCCABE

Telephone: 202-638-7429

E-mail (optional): andrea.mccabe@group.novartis.com

Senate ID #: 9204-12

House ID #: 33589000

7. Client Name: Self

TYPE OF REPORT

8. Year 2004 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: Dec 30, 1899 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): 1,640,102.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: NOVARTIS CORP Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

S1225 Greater Access to Affordable Pharmaceuticals Act

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CASSERLY, DAN

Covered Official Position (if applicable): DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: CASSERLY, DAN

Covered Official Position (if applicable): DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: DRAKE, DAVID

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: DRAKE, DAVID

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: ELKIN, JAMES

Covered Official Position (if applicable): VICE PRESIDENT, FEDERAL GOVERNMENT RELATIONS

Name: ELKIN, JAMES

Covered Official Position (if applicable): VICE PRESIDENT, FEDERAL GOVERNMENT RELATIONS

Name: GILES, THOMAS

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: GILES, THOMAS

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FEDERAL GOVERNMENT RELATIONS

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Registrant Name: NOVARTIS CORP Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

H.R.2218 Regulation of non corrective contact lens as medical devices S.1 Prescription Drug and Medicare Improvement Act of 2003 H.R.1 Medicare Prescription Drug Modernization Act of 2003 H.R.2427 Pharmaceutical Market Access Act of 2003 H.R.1288/S.1037 Access to Cancer Therapies Act of 2003 S.178 Comprehensive Immunosuppressive Drug Coverage for Transplant patients Act of 2003 S.191/H.R.2223 Immunosuppressive drug Coverage Act of 2003 H.R.2356 Prescription Drug Comparative Effectiveness Act of 2003 S.650/H.R.2857 Pediatric Research Equity Act of 2003 H.R.2769 Save our Seniors Act of 2003 H.R.2427 Pharmaceutical Market Access Act of 2003 H.R.1170 Child Medication Safety Act of 2003 H.R.2218 Federal Food, Drug, and Cosmetic Act Medicare Prescription Drugs Breaux/Thomas Medicare Reform Plan Health Insurance Portability and Accessibility Act FDA Modernization Act Medical Records Privacy - Senator jeffords, Bennett, Leahy, Kennedy bills Prospective Payment system Gene Therapy Drug Reimportation Medicare Reform Agriculture Appropriation 2001 - Drug Reimportation Agriculture Appropriation 2001 (FDA Funding) Stem Cell Research Pediatric Exclusivity Direct-to-Consumer Advertising The Bipartisan Medicare Prescription Drug Act of 2001 (Sen. Kennedy-Draft Bill)

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUMBAUGH, DEBORAH

Covered Official Position (if applicable): DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: CASSERLY, DAN

Covered Official Position (if applicable): DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: DRAKE, DAVID

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: ELKIN, JAMES

Covered Official Position (if applicable): VICE PRESIDENT, FEDERAL GOVERNMENT RELATIONS

Name: GILES, THOMAS

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: HALLER, SARAH

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, INTERNATIONAL & PUBLIC AFFAIRS

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Registrant Name: NOVARTIS CORP Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H.R.2218 Regulation of non corrective contact lens as medical devices S1 Prescription Drug and Medicare Improvement Act of 2003
H.R.1 Medicare Prescription Drug Modernization Act of 2003 H.R.2427 Pharmaceutical market Access Act of 2003 H.R.2857 Pediatric Research Equity Act of 2003 H.R.1170 Child Medication Safety Act of 2003 Medicare Prescription Drugs & Modernization Act the Bipartisan Medicare Prescription Drug Act of 2001 (Sen.Kennedy-Draft Bill) Prospective Payment System Medicare Reform

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUMBAUGH, DEBORAH

Covered Official Position (if applicable): DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: CASSERLY, DAN

Covered Official Position (if applicable): DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: DRAKE, DAVID

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: ELKIN, JAMES

Covered Official Position (if applicable): VICE PRESIDENT, FEDERAL GOVERNMENT RELATIONS

Name: GILES, THOMAS

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: HALLER, SARAH

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, INTERNATIONAL & PUBLIC AFFAIRS

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG as its parent, will benefit.

Registrant Name: NOVARTIS CORP Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TAX (one per page)

16. Specific lobbying issues:

H.R.2896 American Jobs Creation Act of 2003 S.1637 Jumpstart Our Business Strength (JOBS) Act

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: DRAKE, DAVID

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: ELKIN, JAMES

Covered Official Position (if applicable): VICE PRESIDENT, FEDERAL GOVERNMENT RELATIONS

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Registrant Name: NOVARTIS CORP Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

Economic Sanction China/World Trade Organization Free Trade Agreements

17. House(s) of Congress and Federal agencies contacted: **None**

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HALLER, SARAH

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, INTERNATIONAL & PUBLIC AFFAIRS

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG as its parent, will benefit.

Signature: ON FILE Date: Feb 10, 2005

Printed Name and Title: DAN CASSELY - DIRECTOR, FEDERAL GOVERNMENT RELATIONS